MINNEAPOLIS--(BUSINESS WIRE)--Respicardia®, a developer of implantable therapies to improve respiratory and cardiovascular health, announced the end of enrollment in the first global pilot study to treat central sleep apnea (CSA) with an implantable system, exceeding the 45-patient milestone. The remede® System, which received CE Mark approval in 2010, delivers electrical pulses during sleep to restore a more normal breathing pattern in patients with CSA. As of this milestone and completion of its pilot study, Respicardia can proceed with the protocol for its pivotal trial. “Completion of over 45 successful implants in the pilot study is a major accomplishment for the company,” said Bonnie Labosky, CEO of Respicardia. “Results from this pilot study give us confidence in moving forward quickly with our pivotal study.”
